Nordisk selected the Clayton site for expansion after an evaluation of both domestic and international facilities. Cost and productivity factors, including the levels of incentive support from local and state resources, were taken into consideration. The Clayton expansion project is approved to receive incentive support from a Job Development Investment Grant and a One North Carolina Fund grant. The company's final decision is contingent upon final approval of local government incentives by Johnston County and Buncombe County.
Indications and Usage: Levemir® (insulin detemir [rDNA origin] injection) is a man-made long-acting insulin that is used to control high blood sugar in adults and children with diabetes mellitus.
Important Safety Information: Check your blood sugar levels. Ask your health care provider what your blood sugars should be and when you should check your blood sugar levels. Alcohol, including beer and wine, may affect your blood sugar when you take Levemir®.
Do not change the type of insulin you use unless told to do so by your health care provider. The amount of insulin you take as well as the best time for you to take your insulin may need to change if you take a different type of insulin.
Never mix Levemir® with other insulin products or use in an insulin pump.
Do not take Levemir® if your blood sugar is too low (hypoglycemia) or if you are allergic to anything in Levemir®. If you take too much Levemir® your blood sugar may fall too low.
Tell your health care provider about all medicines you take and all of your medical conditions, including if you are pregnant or breastfeeding. Your Levemir® dose may change if you take other medicines.
The most common side effect of insulin therapy, including Levemir®, is low blood sugar (hypoglycemia). Other possible side effects include reactions at the injection site (like rednessPage: 1 2 3 Related medicine technology :1
. Novo Nordisk Inc. Announces Exclusive Agreement With Upsher-Smith Laboratories, Inc. to Market Vagifem® 10 mcg2
. Novo Nordisk Addresses Innovation in Diabetes Care in Second Issue of Industry Resource for Information on Diabetes and Chronic Disease3
. Novo Nordisk Announces Resources to Help Support Kids with Diabetes Attending Summer Camp4
. Novo Nordisk Awards More Than $300,000 in Grants to Support Education and Community Health Programs5
. Novo Nordisk partners with international scientific community for Victoza(R) cardiovascular outcomes trial6
. Novo Nordisk Awarded Department of Veterans Affairs National Insulin Contract7
. Novo Nordisks Victoza(R) Receives FDA Approval for Adults With Type 2 Diabetes8
. Novo Nordisk is Changing Possibilities in Hemophilia9
. Novo Nordisk Wins Design Award for NovoTwist(TM) Needle10
. Novo Nordisk New Data From a Phase 3 Study Confirms Clinical Benefits of Once-Daily Liraglutide in the Management of Type 2 Diabetes11
. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market